Criner Gerard J, Bourbeau Jean, Diekemper Rebecca L, Ouellette Daniel R, Goodridge Donna, Hernandez Paul, Curren Kristen, Balter Meyer S, Bhutani Mohit, Camp Pat G, Celli Bartolome R, Dechman Gail, Dransfield Mark T, Fiel Stanley B, Foreman Marilyn G, Hanania Nicola A, Ireland Belinda K, Marchetti Nathaniel, Marciniuk Darcy D, Mularski Richard A, Ornelas Joseph, Road Jeremy D, Stickland Michael K
Temple University School of Medicine, Philadelphia, PA.
Respiratory Epidemiology and Clinical Research Unit, Montreal Chest Institute, McGill University Health Centre, Montreal, QC, Canada.
Chest. 2015 Apr;147(4):894-942. doi: 10.1378/chest.14-1676.
COPD is a major cause of morbidity and mortality in the United States as well as throughout the rest of the world. An exacerbation of COPD (periodic escalations of symptoms of cough, dyspnea, and sputum production) is a major contributor to worsening lung function, impairment in quality of life, need for urgent care or hospitalization, and cost of care in COPD. Research conducted over the past decade has contributed much to our current understanding of the pathogenesis and treatment of COPD. Additionally, an evolving literature has accumulated about the prevention of acute exacerbations.
In recognition of the importance of preventing exacerbations in patients with COPD, the American College of Chest Physicians (CHEST) and Canadian Thoracic Society (CTS) joint evidence-based guideline (AECOPD Guideline) was developed to provide a practical, clinically useful document to describe the current state of knowledge regarding the prevention of acute exacerbations according to major categories of prevention therapies. Three key clinical questions developed using the PICO (population, intervention, comparator, and outcome) format addressed the prevention of acute exacerbations of COPD: nonpharmacologic therapies, inhaled therapies, and oral therapies. We used recognized document evaluation tools to assess and choose the most appropriate studies and to extract meaningful data and grade the level of evidence to support the recommendations in each PICO question in a balanced and unbiased fashion.
The AECOPD Guideline is unique not only for its topic, the prevention of acute exacerbations of COPD, but also for the first-in-kind partnership between two of the largest thoracic societies in North America. The CHEST Guidelines Oversight Committee in partnership with the CTS COPD Clinical Assembly launched this project with the objective that a systematic review and critical evaluation of the published literature by clinical experts and researchers in the field of COPD would lead to a series of recommendations to assist clinicians in their management of the patient with COPD.
This guideline is unique because it provides an up-to-date, rigorous, evidence-based analysis of current randomized controlled trial data regarding the prevention of COPD exacerbations.
慢性阻塞性肺疾病(COPD)是美国乃至世界其他地区发病和死亡的主要原因。COPD急性加重(咳嗽、呼吸困难和咳痰症状的周期性加重)是导致COPD患者肺功能恶化、生活质量受损、需要紧急护理或住院治疗以及护理费用增加的主要因素。过去十年进行的研究极大地增进了我们目前对COPD发病机制和治疗的理解。此外,关于预防急性加重的文献也在不断积累。
认识到预防COPD患者急性加重的重要性,美国胸科医师学会(CHEST)和加拿大胸科学会(CTS)联合制定了基于证据的指南(AECOPD指南),以提供一份实用的、对临床有用的文件,根据主要预防治疗类别描述有关预防急性加重的当前知识状态。使用PICO(人群、干预措施、对照和结局)格式提出的三个关键临床问题涉及COPD急性加重的预防:非药物治疗、吸入治疗和口服治疗。我们使用公认的文献评估工具来评估和选择最合适的研究,提取有意义的数据,并以平衡、无偏见的方式对支持每个PICO问题中建议的证据水平进行分级。
AECOPD指南不仅因其主题——预防COPD急性加重而独特,还因其是北美两个最大的胸科学会之间的首次合作而独特。CHEST指南监督委员会与CTS COPD临床大会合作开展了这个项目,目标是由COPD领域的临床专家和研究人员对已发表的文献进行系统综述和批判性评价,从而得出一系列建议,以帮助临床医生管理COPD患者。
本指南独特之处在于它对当前关于预防COPD加重的随机对照试验数据进行了最新、严谨、基于证据的分析。